The liver is accountable for metabolizing most medications and is therefore one of the primary tissues affected by adverse drug reactions. Most classes of medicine can cause drug-induced liver injury ...

Every January, the world’s largest healthcare investment symposium, the J.P. Morgan Healthcare Conference (JPM 2026), offers ...

Right now leaders from both the private and public sectors are gathering at COP29 in Baku, Azerbaijan—where one of the leading topics is how to finance the pursuit of net-zero. Reaching that goal will ...

As the leading manufacturer in C&I energy storage market, JDEnergy has delivered more than 30,000 eBlocks across over 2,000 C&I sites worldwide. This track record reflects sustained innovation in ...

The comparison between “strategic decoupling” and “de-risking” provides a framework for analyzing how each candidate of the upcoming U.S. presidential election approaches economic security policies.

Pilot-plant success is one of the biggest de-risking moments in resources investing, proving the process works at scale For companies like Elevate Uranium, Pursuit Minerals and Green Critical Minerals ...

Viral vectors are critical vehicles for the delivery of life-saving cell and gene therapies. Adeno-associated virus (AAV) and lentiviral vectors (LVV), two of the most widely used vector platforms, ...

Over 70% to 90% of early-stage renewable energy projects fail to reach construction, said a whitepaper from Paces, a platform for renewable energy project development and de-risking. Early-stage clean ...

QuantumScape's Alpha-2 prototype delivery marks significant progress towards commercialization of solid-state batteries, potentially revolutionizing the EV industry. Strategic partnership with PowerCo ...

We’re in the midst of a paradigm shift in biomarker science. Once considered exploratory, biomarker signatures have evolved into strategic assets - tools that actively de-risk decision-making across ...

Antibody-drug conjugates (ADCs) represent the most successful class of active targeting drug-delivery systems, however, despite the increasing number of FDA approvals treatment-related adverse events ...